欧洲药物辅助治疗 (MAT) 市场，按类型（药物和疗法）、产品（丁丙诺啡和纳洛酮、纳曲酮、丁丙诺啡、美沙酮、纳洛酮、双硫仑和阿坎酸）、药物类型（仿制药和品牌药）、剂型（速释剂和缓释剂）、给药途径（口服、肠胃外和其他）、人群类型（成人和青少年）、最终用户（康复诊所、医院、专科中心、家庭护理和其他）分销渠道（医院药房、直接招标、零售药房、网上药房和其他）、行业趋势和预测到 2029 年
市场分析和见解
食品药品管理局(FDA)批准了三种临床药物:丁丙诺啡,美沙酮,和纳特莱克松. 药物辅助治疗(MAT)用于治疗酒精使用障碍、阿片依赖药物和阿片过量预防药物。 酒精使用障碍(AUD)是一种医疗状况,其特点是,尽管在社会、职业或健康方面造成了不良后果,但停止酒精使用的能力仍然受损。 Acamprosate, disulfiram,和Naltrexone是最常见的用于治疗酒精使用障碍(AUD)的药物. 类阿片依赖药物,病人对类阿片的上瘾率上升。 丁诺啡,美沙酮,和纳特雷斯酮被用于将类阿片使用障碍治疗为海洛因,吗啡等短效类阿片和可待因等类阿片,以及催产酮和氢可可酮等半合成类阿片. 这些MAT药物在几个月,几年,甚至一生中都是安全的.
市场定义
药物辅助治疗(MAT)涉及使用药物,结合咨询和行为疗法,为治疗药物使用障碍提供完整的病人方法。 MAT的目标是适当的康复,包括改善病人存活率,增加治疗保留率,减少非法反应,以及增加妇女怀孕结果。 对于类阿片过量预防药物,使用纳克酮来通过逆转过量的毒性影响来防止类阿片过量. 据世界卫生组织(卫生组织)和药物滥用和精神保健服务管理局(SAMHSA)称,纳克酮是许多被认为对运作良好的保健系统至关重要的药物之一。 欧洲药物辅助治疗是支持性的,旨在降低症状的严重程度. 数据桥市场研究(Data Bridge Market Research)分析认为,药物辅助治疗(MAT)市场将在2022年至2029年以8.7%的CAGR增长.
|
报表计量 |
细节 |
|
预测期 |
2022至2029年统计 |
|
基准年 |
2021 |
|
历史年代 |
2020年(2019-2014年可定制). |
|
数量单位 |
收入(百万美元),定价(美元) |
|
覆盖部分 |
按类型(药物和治疗)、产品(布普诺尔芬和纳洛克松、纳特雷克松、布普尔诺尔芬、美沙酮、纳洛克松、迪苏勒菲拉姆和阿坎普罗萨特)、药物类型(基因和品牌)、剂量表(立即释放和扩大释放)、管理路线(Oral、家长和其他)、人口类型(Adults和青少年)、终端用户(康复诊所、医院、专科中心、家庭护理等)分发渠道(医院药房、直接招标、零售药房、在线药房等) |
|
涵盖国家 |
德国、法国、英国、意大利、西班牙、俄罗斯、土耳其、荷兰、瑞士、挪威、波兰、匈牙利、立陶宛、奥地利、爱尔兰和欧洲其他地区。 |
|
覆盖的市场玩家 |
(原始内容存档于2018-10-21). Indivior PLC, Alkermes. 太阳制药业有限公司,泰吉制药有限责任公司,海克玛制药PLC,辉瑞股份有限公司,协和保健(Intas制药的子公司),Glenmark制药股份有限公司,Mallinckrodt,Alvogen,Teva制药工业有限公司. Dr. Reddy's Laboratories Ltd. Amneal制药有限责任公司. |
欧洲药品辅助治疗市场动态
司机
- . 类阿片发病率上升使用疾病(类阿片依赖药物)
药物辅助治疗(MAT)是指结合咨询和行为疗法使用药物,提供"全病人"治疗药物使用障碍的方法. MAT中使用的药物由食品和药品管理局(FDA)批准,MAT方案由临床驱动并量身定制以满足每个病人的需求.
比如说,
- 欧洲成年人(15-64岁)中高风险类阿片使用(注射或长期/定期使用)的流行率多年来一直相对稳定,估计使用者约占欧盟人口的0.35%。
由于这些公司不断从事研究和开发活动,了解酗酒和类阿片使用失调的发生率将有助于找到新的解决办法,并将有助于与美国、欧洲和亚太区域等国家的市场参与者开展更多的合作并建立伙伴关系。 这表明与研发有关的投资增加,用于启动药物辅助治疗的非专利药品(MAT),这将促进市场增长。
- 政府为药品辅助治疗提供的资金
尽管治疗类阿片使用和酒精紊乱的药效已经得到确认,但人们注意到,专科治疗方案对实施戒毒治疗药物的限制。 需要特别注意资金、组织结构和劳动力资源的具体来源,进行长期投资,使付款与未来可能的受益者保持一致。
比如说,
- 2021年2月,资助了综合药物使用失调症培训方案(ISTP),为执业护士和药物辅助治疗医生助理(MAT)计划、制定和开办为期12个月的全时或24个月的半时培训方案。 资金用于扩大受过培训的劳动力队伍,为需要心理健康和阿片类药物使用障碍预防的个人提供护理
政府提供的资金将保证病人的安全,并节省费用。 此外,医院和保健机构将通过与政府组织合作,以更低的价格管理这种治疗。 因此,研究与发展活动的进展以及政府提供的资金可望推动市场增长。
机会
- 保健支出上升
此外,研究和发展活动的增加以及政府和私营组织投资的增加将增加市场增长率的新机会。
比如说,
- 2021年12月,欧统局称,欧洲联盟的保健支出为13.096亿美元。
不断增加的保健支出也有利于保健部门的进一步发展和增长。 此外,人口可支配收入的增加也是一个有利因素。 预计上述情况将为药物辅助治疗市场创造有利可图的机会。
限制/挑战
- 严格条例
公司必须仔细审查产品规格和认证,然后按照食品和药品管理局和欧洲联盟(欧盟)对其产品进行分类。 每个国家的管制当局都负责执行药品开发、许可证发放、登记、制造、销售和标签的规则和条例。
比如说,
- 在德国,联邦政府、医药和保健产品管理局(MHRA)在药物辅助治疗(MAT)被视为医药产品时,对酒精紊乱和类阿片过量紊乱的治疗进行规范和提供指导方针,用于质量和安全(Q和S)测试条例。
监管部门要与科研人员更紧密地合作,即使涉及商业企业,监管部门也要更迅速,更高效地做好所监管的一切事项的处理和审批工作. 制造商必须确保在向监管当局提交产品核准申请之前,掌握全部产品功效数据。 因此,严格的管制框架导致产品在市场上迟发。 这意味着,僵硬的监管框架预计将对市场增长构成挑战。
药品辅助(MAT)治疗市场报告详细介绍了近期新发展,贸易监管,进出口分析,生产分析,价值链优化,市场份额,国内和本地化市场主体影响等情况,从新兴收入领域,市场监管变化,战略性市场增长分析,市场规模,类别市场增长,应用优势和支配地位,产品审批,产品推出,地域扩张,市场技术创新等方面分析机遇. 为了获得更多关于药物辅助治疗(MAT)市场联系数据桥市场研究的信息,我们团队将帮助你做出知情的市场决定,实现市场增长.
影响药品辅助治疗市场
在这一流行病期间,药物辅助治疗显著地降低了COVID-19患者的死亡率和发病率。 需要进一步进行大规模研究,以核准这些结果。 应对COVID-19感染药物辅助治疗规程进行界定,以取得最佳临床结果。 在Covid-19药物治疗期间,针对类阿片使用紊乱症的服务进行了临床试验,这是解决类阿片危机的关键所在,而COVID-19对提供类阿片使用紊乱症产生了重大影响。
最近的发展
- 2021年4月,阿达米斯制药公司与USWM公司宣布推出并供应高剂量的ZIMHI可注射纳克酮产品来帮助对抗类阿片过量死亡. 预计启动将增加产品部门收入,这将促进市场增长,ZIMHI将以折扣率提供给第一反应者和社区保健组织
欧洲药物辅助治疗市场范围
药物辅助治疗(MAT)市场按8个部分划分:类型、产品、药物类型和剂量形式、管理途径、人口类型、最终用户和分配渠道。 这些部门的增长将有助于你分析这些行业中增长不足的部分,并为用户提供宝贵的市场概况和市场见解,帮助他们作出确定核心市场应用的战略决定。
类型
- 药品
- 治疗
根据类型,欧洲药物辅助治疗市场被划分为:药物治疗
产品
- 丁诺啡和纳洛克酮
- 纳特雷克松
- 布普罗诺芬
- 美沙酮
- 纳洛克酮
- 迪苏菲拉姆
- 营地
在产品的基础上,欧洲药物辅助治疗市场被分解成丁丙诺啡和纳克酮、纳克勒克酮、丁丙诺啡、美沙酮、纳克勒克酮、去甲磺酰胺和丙烯酸。
药物类型
- 常规
- 品牌
根据药物类型,欧洲药物辅助治疗(MAT)市场被分割成通用药品并被打上烙印.
剂量表单
- 立即释放
- 扩展发行
根据剂量表,欧洲药物辅助治疗(MAT)市场被分割为立即释放和延长释放。
行政路线
- 口头
- 家长
- 其他人员
根据管理路线,欧洲药物辅助治疗市场被分割为:口头、亲子关系等。
人口类型
- 成年人
- 青少年
根据人口类型,欧洲药物辅助治疗市场分为成年人和青少年。
结束用户
- 康复诊所
- 医院
- 专业中心
- 家庭护理
- 其他人员
在最终用户的基础上,欧洲药物辅助治疗市场分为康复诊所、医院、专科中心、家庭护理等。
分发频道
- 医院药房
- 直接招标
- 零售药店
- 在线药店
- 其他人员
根据分销渠道,欧洲药物辅助治疗市场分为医院药房、直接招标、零售药房、在线药房等。
药品辅助治疗市场区域分析/见解
对欧洲药物辅助治疗市场进行了分析,并按区域、产品类型、类型、应用、工作流程、最终用户和分销渠道提供了市场规模的见解和趋势。
药物辅助治疗市场报告涵盖的国家有德国、法国、联合王国、意大利、西班牙、俄罗斯、土耳其、荷兰、瑞士、挪威、波兰、匈牙利、立陶宛、奥地利、爱尔兰和欧洲其他地区。
由于MAT康复中心的存在,报销额增加,以及制药公司的兴起,预计德国将主导市场。
报告的国家部分还提供了影响当前和未来市场趋势的个别市场影响因素和国内监管变化。 新的销售、替代销售、国家人口统计、疾病流行病学和进出口关税等数据点是用来预测个别国家市场情况的一些主要指针。 此外,在提供国家数据的预测分析的同时,还考虑了全球品牌的存在和可得性以及它们因来自当地和国内品牌的大规模或稀缺的竞争而面临的挑战以及销售渠道的影响。
竞争性景观和药品辅助治疗市场共享分析
欧洲药物辅助治疗市场竞争环境提供了竞争者的详情。 详细情况包括公司概况、公司财务、创收、市场潜力、研发投资、新市场举措、欧洲存在、生产地点和设施、生产能力、公司优势和弱点、产品推出、产品宽度和广度、应用优势。 上述数据点只涉及公司对药物援助治疗市场的关注。
在药物辅助治疗(MAT)市场运营的一些主要角色有Indivior PLC,Alkermes. 太阳制药业有限公司,泰吉制药有限责任公司,海克玛制药PLC,辉瑞股份有限公司,协和保健(Intas制药的子公司),Glenmark制药股份有限公司,Mallinckrodt,Alvogen,Teva制药工业有限公司. Dr. Reddy's Laboratories Ltd. Amneal制药有限责任公司.
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EPIDEMIOLOGY
4.2 PESTEL
4.3 PORTER'S FIVE FORCES MODEL
4.4 ANNUAL INCIDENCE OF SUBJECTS ENTERING MEDICATION-ASSISTED TREATMENT IN ALCOHOL, OPIOID USE DISORDER, AND OPIOID OVERDOSE PREVENTION (2021)
4.5 ANNUAL NUMBER OF TREATMENTS WITH CLONIDINE AND WITH LOFEXIDINE IN OPIOID USE DISORDER AND OPIOID OVERDOSE PREVENTION (2021)
4.6 ANNUAL INCIDENCE OF INDIVIDUALS RE-ENTERING MEDICATION-ASSISTED TREATMENT. FOR EXAMPLE, SOMEONE MAY DROP OUT OF TREATMENT AND RESTART TREATMENT LATER (2021)
4.7 ANNUAL USE OF NALTREXONE INJECTION AS PART OF TREATMENT FOR THE INITIAL WITHDRAWAL FROM OPIOIDS, AND ANNUAL MAINTENANCE THERAPY USING NALTREXONE INJECTION (2021)
4.8 PIPELINE ANALYSIS FOR MEDICATION-ASSISTED TREATMENT (MAT) MARKET
5 EUROPE MEDICATION-ASSISTED TREATMENT MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 THE RISE IN INCIDENCE OF ALCOHOL USE DISORDER AND OPIOID USE DISORDERS
6.1.2 THE FUNDING BY THE GOVERNMENT FOR MEDICATION-ASSISTED TREATMENT (MAT)
6.1.3 THE RISE IN THE POPULATION RECEIVING MEDICATION-ASSISTED TREATMENT (MAT) AND MEDICATION-ASSISTED AWARENESS PROGRAMMESMEDICATION-ASSISTED TREATMENT (MAT)
6.1.4 USE OF REIMBURSEMENT FOR MEDICATION-ASSISTED TREATMENT (MAT)
6.2 RESTRAINTS
6.2.1 SIDE EFFECTS OF DRUGS USED IN MEDICATION-ASSISTED TREATMENT (MAT)
6.2.2 ETHICAL ISSUES RELATED TO USE OF MEDICATION-ASSISTED TREATMENTMEDICATION-ASSISTED TREATMENT (MAT)
6.2.3 RISE IN PRODUCT RECALLS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
6.3.2 RISE IN HEALTHCARE EXPENDITURE
6.4 CHALLENGES
6.4.1 THE LACK OF SKILLED PROFESSIONALS, REQUIRED FOR MEDICATION-ASSISTED TREATMENT
6.4.2 STRINGENT REGULATIONS
6.4.3 DISCONTINUATION OF MEDICATION-ASSISTED TREATMENT (MAT)
7 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE
7.1 OVERVIEW
7.2 MEDICATION
7.2.1 OPIOID DEPENDENCY MEDICATION
7.2.1.1 BUPRENORPHINE AND NALOXONE
7.2.1.2 BUPRENORPHINE
7.2.1.3 METHADONE
7.2.1.4 NALTREXONE
7.2.2 ALCOHOL USE DISORDER MEDICATIONS
7.2.2.1 NALTREXONE
7.2.2.2 DISULFIRAM
7.2.2.3 ACAMPROSATE
7.2.3 OPIOID OVERDOSE PREVENTION MEDICATION
7.2.3.1 NALOXONE
7.3 THERAPY
7.3.1 BEHAVIORAL THERAPY
7.3.2 EDUCATIONAL THERAPY
7.3.3 COUNSELLING
7.3.4 VOCATIONAL THERAPY
7.3.5 OTHERS
8 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS
8.1 OVERVIEW
8.2 BUPRENORPHINE AND NALOXONE
8.3 NALTREXONE
8.4 BUPRENORPHINE
8.5 METHADONE
8.6 NALOXONE
8.7 DISULFIRAM
8.8 ACAMPROSATE
9 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 GENERICS
9.3 BRANDED
9.3.1 SUBOXONE
9.3.2 VIVITROL
9.3.3 BUTRANS
9.3.4 ZUBSOLV
9.3.5 PROBUPHINE
9.3.6 OTHERS
10 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM
10.1 OVERVIEW
10.2 IMMEDIATE RELEASE
10.3 EXTENDED RELEASE
11 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.2.1 TABLET
11.2.2 SUBLINGUAL FILM
11.2.3 OTHERS
11.3 PARENTERAL
11.3.1 SOLUTION
11.3.2 SUSPENSION
11.4 OTHERS
12 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE
12.1 OVERVIEW
12.2 ADULTS
12.3 TEENAGE
13 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER
13.1 OVERVIEW
13.2 REHABILITATION CLINICS
13.3 HOSPITALS
13.4 SPECIALTY CENTERS
13.5 HOMECARE
13.6 OTHERS
14 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 DIRECT TENDER
14.4 RETAIL PHARMACY
14.5 ONLINE PHARMACY
14.6 OTHERS
15 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION
15.1 EUROPE
15.1.1 GERMANY
15.1.2 FRANCE
15.1.3 U.K.
15.1.4 ITALY
15.1.5 RUSSIA
15.1.6 SPAIN
15.1.7 NETHERLANDS
15.1.8 SWITZERLAND
15.1.9 NORWAY
15.1.10 POLAND
15.1.11 HUNGARY
15.1.12 LITHUANIA
15.1.13 AUSTRIA
15.1.14 IRELAND
15.1.15 TURKEY
15.1.16 REST OF EUROPE
16 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: EUROPE
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2021)
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 INDIVOR PLC (2021)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 VIATRIS INC (2021)
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 SUN PHARMACEUTICAL INDUSTRIES LTD (2021)
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 ALKERMES (2021)
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 PURDUE PHARMA L.P. (2021)
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENTS
18.7 PFIZER (2021)
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 GLENMARK PHARMACEUTICAL INC (2021)
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 DR. REDDY’S LABORATORIES LTD (2021)
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.1 ALVOGEN (2021)
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENTS
18.11 ADAMIS PHARMACEUTICALS CORPORATION (2021)
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 ACCORD HEALTHCARE (A SUBSIDIARY OF INTAS PHARMACEUTICALS)
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENTS
18.13 AMNEAL 製藥有限責任公司 (2021)
18.13.1 公司概況
18.13.2 收入分析
18.13.3 產品組合
18.13.4 近期發展
18.14 美國成癮中心（2021 年）
18.14.1 公司概況
18.14.2 產品組合
18.14.3 近期發展
18.15 HIKMA 製藥股份有限公司 (2021)
18.15.1 公司概況
18.15.2 收入分析
18.15.3 產品組合
18.15.4 近期發展
18.16 蘭內特 (2021)
18.16.1 公司概況
18.16.2 收入分析
18.16.3 產品組合
18.16.4 最近的發展
18.17 馬林克羅德 (2021)
18.17.1 公司概況
18.17.2 收入分析
18.17.3 產品組合
18.17.4 最近的發展
18.18 OREXO US INC（OREXO, INC 的子公司）（2021 年）
18.18.1 公司概況
18.18.2 收入分析
18.18.3 產品組合
18.18.4 最近的發展
18.19 巔峰治療中心
18.19.1 公司概況
18.19.2 產品組合
18.19.3 最近的發展
18.2 美國的復健中心
18.20.1 公司概況
18.20.2 產品組合
18.20.3 近期發展
18.21 泰姬製藥有限公司
18.21.1 公司概況
18.21.2 產品組合
18.21.3 近期發展
18.22 泰坦製藥 (2021)
18.22.1 公司概況
18.22.2 收入分析
18.22.3 產品組合
18.22.4 近期發展
18.23 VISTAPHARM, INC（VERTICE PHARMA, LLC.的子公司（2021））
18.23.1 公司概況
18.23.2 產品組合
18.23.3 近期發展
19 問卷
20份相關報告
表格列表
TABLE 1 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 EUROPE MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 EUROPE MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 EUROPE OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 5 EUROPE ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 EUROPE OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 EUROPE THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 10 EUROPE BUPRENORPHINE AND NALOXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE NALTREXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE BUPRENORPHINE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE METHADONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE NALOXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE DISULFIRAM IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 EUROPE ACAMPROSATE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 18 EUROPE GENERICS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 21 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 22 EUROPE IMMEDIATE RELEASE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE EXTENDED RELEASE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 31 EUROPE ADULTS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE TEENAGE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 EUROPE REHABILITATION CLINICS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE HOSPITALS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 EUROPE SPECIALTY CENTERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 EUROPE HOMECARE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 EUROPE OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 40 EUROPE HOSPITAL PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 EUROPE DIRECT TENDER IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 EUROPE RETAIL PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 EUROPE ONLINE PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 44 EUROPE OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 45 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 46 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 EUROPE MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 EUROPE OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 EUROPE ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 EUROPE OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 EUROPE THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 53 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 54 EUROPE BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 55 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 56 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 57 EUROPE ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 58 EUROPE PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 59 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 60 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 61 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 62 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 GERMANY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 GERMANY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 GERMANY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 GERMANY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 GERMANY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 69 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 70 GERMANY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 71 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 72 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 73 GERMANY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 74 GERMANY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 75 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 76 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 77 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 78 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 FRANCE MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 FRANCE OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 FRANCE ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 FRANCE OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 FRANCE THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 84 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 85 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 86 FRANCE BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 87 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 88 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 89 FRANCE ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 90 FRANCE PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 91 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 92 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 94 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 95 U.K. MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 U.K. OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 U.K. ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 U.K. OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 U.K. THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 101 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 102 U.K. BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 103 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 104 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 105 U.K. ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 106 U.K. PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 107 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 108 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 109 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 ITALY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 112 ITALY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 113 ITALY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 ITALY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 ITALY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 117 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 118 ITALY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 119 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 120 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 121 ITALY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 122 ITALY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 123 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 124 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 125 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 126 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 127 RUSSIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 RUSSIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 RUSSIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 RUSSIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 RUSSIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 132 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 133 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 134 RUSSIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 135 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 136 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 137 RUSSIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 138 RUSSIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 139 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 140 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 141 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 142 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 143 SPAIN MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 SPAIN OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 SPAIN ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 SPAIN OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 147 SPAIN THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 148 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 149 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 150 SPAIN BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 151 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 152 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 153 SPAIN ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 154 SPAIN PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 155 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 156 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 157 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 158 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 159 NETHERLANDS MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 NETHERLANDS OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 161 NETHERLANDS ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 162 NETHERLANDS OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 163 NETHERLANDS THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 164 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 165 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 166 NETHERLANDS BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 167 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 168 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 169 NETHERLANDS ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 170 NETHERLANDS PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 171 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 172 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 173 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 174 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 175 SWITZERLAND MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 SWITZERLAND OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 177 SWITZERLAND ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 SWITZERLAND OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 179 SWITZERLAND THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 180 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 181 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 182 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 183 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 184 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 185 SWITZERLAND ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 186 SWITZERLAND PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 187 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 188 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 189 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 190 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 191 NORWAY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 192 NORWAY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 NORWAY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 194 NORWAY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 195 NORWAY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 196 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 197 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 198 NORWAY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 199 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 200 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 201 NORWAY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 202 NORWAY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 203 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 204 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 205 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 206 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 207 POLAND MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 208 POLAND OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 209 POLAND ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 210 POLAND OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 211 POLAND THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 212 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 213 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 214 POLAND BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 215 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 216 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 217 POLAND ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 218 POLAND PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 219 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 220 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 221 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 222 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 223 HUNGARY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 224 HUNGARY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 225 HUNGARY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 226 HUNGARY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 227 HUNGARY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 228 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 229 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 230 HUNGARY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 231 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 232 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 233 HUNGARY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 234 HUNGARY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 235 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 236 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 237 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 238 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 239 LITHUANIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 240 LITHUANIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 241 LITHUANIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 LITHUANIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 243 LITHUANIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 244 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 245 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 246 LITHUANIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 247 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 248 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 249 LITHUANIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 250 LITHUANIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 251 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 252 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 253 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 254 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 255 AUSTRIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 256 AUSTRIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 257 AUSTRIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 258 AUSTRIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 259 AUSTRIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 260 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 261 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 262 AUSTRIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 263 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 264 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 265 AUSTRIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 266 AUSTRIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 267 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 268 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 269 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 270 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 271 IRELAND MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 272 IRELAND OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 273 IRELAND ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 274 IRELAND OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 275 IRELAND THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 276 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 277 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 278 IRELAND BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 279 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 280 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 281 IRELAND ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 282 IRELAND PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 283 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 284 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 285 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 286 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 287 TURKEY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 288 TURKEY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 289 TURKEY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 290 TURKEY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 291 TURKEY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 292 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 293 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 294 TURKEY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 295 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 296 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 297 TURKEY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 298 TURKEY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 299 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 300 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 301 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 302 REST OF EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET : SEGMENTATION
FIGURE 2 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DBMR POSITION GRID
FIGURE 8 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: END USER COVERAGE GRID
FIGURE 10 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASED INCIDENCE OF ALCOHOL USE DISORDERS AND RISE IN PRODUCT APPROVALS IS EXPECTED TO DRIVE EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET FROM 2022 TO 2029
FIGURE 13 TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET FROM 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET
FIGURE 15 INCIDENCE OF ALCOHOL CONSUMPTION IN 2019
FIGURE 16 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, 2021
FIGURE 17 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, 2021
FIGURE 21 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, 2022-2029 (USD MILLION)
FIGURE 22 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, CAGR (2022-2029)
FIGURE 23 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, LIFELINE CURVE
FIGURE 24 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, 2021
FIGURE 25 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)
FIGURE 26 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 27 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, 2021
FIGURE 29 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, 2022-2029 (USD MILLION)
FIGURE 30 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 31 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 32 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 33 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 34 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 35 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, 2021
FIGURE 37 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION)
FIGURE 38 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, CAGR (2022-2029)
FIGURE 39 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 40 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, 2021
FIGURE 41 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 42 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, CAGR (2022-2029)
FIGURE 43 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 45 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 46 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 47 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)
FIGURE 49 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021)
FIGURE 50 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 51 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 52 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)
FIGURE 53 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
